Navigation Links
Unigene Announces Positive Top-Line Results of Phase 2 Oral PTH Study for the Treatment of Osteoporosis in Postmenopausal Women
Date:11/9/2011

ry endpoints evaluated biochemical markers of bone formation and resorption, as well as the safety, tolerability and pharmacokinetics of the oral formulation.

About Unigene-GSK Exclusive Worldwide Licensing Agreement

On December 10, 2010, Unigene entered into an amended and restated exclusive worldwide license agreement with GSK to develop and commercialize an oral formulation of a recombinantly produced PTH analog for the treatment of osteoporosis in postmenopausal women. Under the terms of the amended and restated agreement, Unigene was responsible for the manufacture of the PTH and the conduct of the Phase 2 study. To date, the Company received a total of $8 million in relation to the Phase 2 study.  Unigene is eligible to receive further payments of up to approximately $140 million based on the achievement of regulatory and commercialization milestones. In addition, Unigene is eligible to receive tiered double-digit royalties in the low-to-mid teens on global sales. Based on a review of the Phase 2 data, GSK may elect to assume responsibility for all future development and commercialization of the product.

Unigene will formally submit the Phase 2 Clinical Study Report to GSK by the end of the year.  GSK has up to 75 days following submission of the report to inform Unigene whether it will proceed with the clinical development of the oral formulation of a recombinantly produced PTH analog for the treatment of osteoporosis in postmenopausal women pursuant to the terms of the exclusive worldwide licensing agreement.

About Osteoporosis

Osteoporosis is a disease in which bones become brittle and so are more likely to break. In osteoporotic women and men, the density and quality of bone are reduced, leading to deterioration of the skeleton and increased risk of fracture. It's often diagnosed only after an osteoporosis-related fracture happens because prior to such an event, the patient has no outward signs or
'/>"/>

SOURCE Unigene Laboratories, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Tarsa Therapeutics and Unigene Present Preclinical Data Suggesting Calcitonin May Have Utility in Combination Therapy for the Treatment of Osteoarthritis
2. China-Biotics, Inc. Announces Conference Call to Discuss First Quarter 2009 Financial Results
3. Odyssey Thera Announces Milestone Achievement in Pfizer Alliance
4. InNexus Biotechnology Announces Launch of Large Scale Primate Study of DXL625
5. Anesiva Announces Second Quarter 2008 Financial Results and Update
6. SGX Pharmaceuticals Announces Financial Results for the Three and Six Months Ended June 30, 2008
7. Insmed Announces Financial Results for Second Quarter and Six-Months Ended June 30, 2008
8. China Sky One Medical, Inc. Announces Conference Call to Discuss Second Quarter 2008 Results
9. China Yingxia International, Inc. Announces Conference Call to Discuss Second Quarter 2008 Results
10. ThirdBiotech Announces Kemeta as Newest Sponsor
11. Signalife Announces Intent to Withdraw From AMEX and Trade on the OTCBB
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... , July 30, 2015 ... santé, publie ses résultats pour le premier semestre ... commente les résultats. Visionner l,interview vidéo ... http://www.eurobusinessmedia.com/ceo-direct/sanofi/sanofi-h1-2015-results-interview-with-ceo-olivier-brandicourt?utm_source=ceo-direct&utm_medium=wire Au sommaire de l,interview ... - Moteurs de croissance - Diabète ...
(Date:7/29/2015)... / Japan (Q2 2015: +14% CER / 20% of ... growth in China , as well as solid contributions from ... Europe / Middle East / ... gains in Germany , Turkey and ... / 49% of sales) grew 11%, excluding U.S. HPV sales, on demand across ...
(Date:7/29/2015)... 2015  AsureQuality and Ubiquitome have agreed to ... in food and primary production sectors. The collaboration ... device, the Freedom4. AsureQuality provides quality ... supermarket shelf for producers, processors and Competent Authorities ... disease control and pest management and surveillance programmes. ...
(Date:7/29/2015)... , ... July 29, 2015 , ... ... today announced its GHS Label Guide . To align chemical container labeling ... this guide includes explanations of label components, an example of an accurate label, ...
Breaking Biology Technology:QIAGEN Reports Results for Second Quarter and First Half of 2015 2QIAGEN Reports Results for Second Quarter and First Half of 2015 3QIAGEN Reports Results for Second Quarter and First Half of 2015 4QIAGEN Reports Results for Second Quarter and First Half of 2015 5QIAGEN Reports Results for Second Quarter and First Half of 2015 6QIAGEN Reports Results for Second Quarter and First Half of 2015 7QIAGEN Reports Results for Second Quarter and First Half of 2015 8QIAGEN Reports Results for Second Quarter and First Half of 2015 9QIAGEN Reports Results for Second Quarter and First Half of 2015 10AsureQuality and Ubiquitome Partner on Applications for Mobile Molecular Food Safety Testing 2Brady Announces a New GHS Label Guide 2
... SPEX ) reported that on July 21, 2008, ... the bid price of the,Company,s common stock for the ... minimum $1.00 per share required for continued listing,on NASDAQ. ... the Common Stock at,this time., Spherix has been ...
... July 23 Duska Therapeutics,Inc. (OTC Bulletin Board: ... comment a synopsis of a proposed Phase 3 ... U.S. Food and Drug Administration,s (the,"FDA") Division of ... communications with the FDA, including a face-to-face,meeting held ...
... July 23 NxStage Medical,Inc. (Nasdaq: NXTM ... announced ongoing public access to current summary,information derived ... (ESRD) who undergo hemodialysis at home on a ... the conventional regimen of therapy,received three times a ...
Cached Biology Technology:Spherix Receives NASDAQ Bid Price Deficiency Letter 2Duska Therapeutics Submits Phase 3 ATPace(TM) Protocol to FDA for Comment 2Duska Therapeutics Submits Phase 3 ATPace(TM) Protocol to FDA for Comment 3Duska Therapeutics Submits Phase 3 ATPace(TM) Protocol to FDA for Comment 4NxStage Announces Access to Demographic and Outcomes Information for the Growing U.S. Daily Home Hemodialysis Patient Population 2NxStage Announces Access to Demographic and Outcomes Information for the Growing U.S. Daily Home Hemodialysis Patient Population 3NxStage Announces Access to Demographic and Outcomes Information for the Growing U.S. Daily Home Hemodialysis Patient Population 4NxStage Announces Access to Demographic and Outcomes Information for the Growing U.S. Daily Home Hemodialysis Patient Population 5
(Date:7/31/2015)... 31, 2015 NXT-ID, Inc. (NASDAQ: NXTD ) ... on the growing mobile commerce market and creator of ... provisional patent 62/198989 for ELECTRONIC CRYPTO-CURRENCY MANAGEMENT ... method to advance crypto-currencies such as Bitcoin into the ... uniform way to manage all payments.  ...
(Date:7/30/2015)... MOUNTAIN VIEW, Calif. , July 30, 2015 ... products and services for gene function analysis and ... CRISPR Guide RNA (sgRNA) Knockout Library targeting all ... to specifically and permanently "knock out" a gene,s ... library provides a high throughput screening tool so ...
(Date:7/27/2015)... , July 27, 2015   Zynx Health ... experience-based clinical improvement solutions, today announced that its ... now available on Android smartphones and tablets. With ... post-care organizations can use ZynxCarebook to securely exchange ... condition, streamline care transitions to other care settings, ...
Breaking Biology News(10 mins):NXT-ID Patents Electronic Crypto-Currency Management Technology 2NXT-ID Patents Electronic Crypto-Currency Management Technology 3NXT-ID Patents Electronic Crypto-Currency Management Technology 4CELLECTA, INC. Announces Launch of Human Whole Genome CRISPR Knockout Library 2Zynx Health Adds Android Device Support to ZynxCarebook Solution 2Zynx Health Adds Android Device Support to ZynxCarebook Solution 3
... historic meeting next week may decide the fate of tuna ... important marine resources. The Inter-American Tropical Tuna Commission ... 27 in Panama City, Panama, to reverse a trend ... of tuna stocks. Failure of the IATTC to compromise effectively ...
... in gaining major European Union funding to begin ... such as DNA, can be managed and made ... Centre for Integrated Genomic Medical Research (CIGMR), based ... a key role in developing the Biobanking and ...
... Worker Identification Credential (TWIC) Program, Ensures No ... MIAMI BEACH, Fla., June 17 ... high-performance solutions for trusted,credential assurance, reported that ... critical software to the Transportation Security Agency,s ...
Cached Biology News:Tuna populations at risk 2Manchester clears first hurdle in €170 million biobank building boom 2ID Solutions Awarded Full-Production Order for Fingerprint Processing Software for TWIC 2
... in Ham's F12K medium with 2 mM L-glutamine ... In order to keep the antigens in their ... cells are arrayed on a 12-well (5 mm) ... treated to enhance cellular attachment and to minimize ...
Mouse polyclonal antibody to REXO4 - XPMC2 prevents mitotic catastrophe 2 homolog (Xenopus laevis)...
... Stabilizer is an aqueous solution that contains ... chemicals in a PBS buffer (phosphate buffered ... product contains a combination of 0.02% methylisothiazolone ... StabilCoat Plus Stabilizer provides optimum performance for ...
... trays are disposable trays that ... that have been blotted onto ... eight 10.5 cm x 5 ... cut from blotted membrane and ...
Biology Products: